KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis.
KY-62 is a water-soluble analog of amphotericin B. In vitro testing of five clinical isolates of Candida albicans showed KY-62 to have potency similar to that of amphotericin B. KY-62 was administered to mice infected intravenously with C. albicans. In vivo, KY-62 was effective in immunocompetent mice, with potency similar to that of amphotericin B. KY-62 was well tolerated up to 30 mg/kg of body weight per dose, an amount that would be lethal with amphotericin B. KY-62 was less effective in mice rendered neutropenic with 5-fluorouracil. The addition of flucytosine had little effect. KY-62 may have potential for clinical development.
Graybill
J R
JR
University of Texas Health Science Center, San Antonio 78284, USA. graybill@uthscsa.edu
Najvar
L K
LK
Fothergill
A
A
Hardin
T
T
Rinaldi
M
M
Lambros
C
C
Regen
S L
SL
D000666:Amphotericin B / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D051379:Mice
D000935:Antifungal Agents; C110373:KY-62; D000666:Amphotericin B